Session Descriptions

Sunday June 2
​1 contact hour
John Moulds Memorial Lecture
Provision of Blood for the Highly Immunized Patient
Presented by:  Sandra Nance, MS, MT(ASCP)SBB; Senior Director, IRLs, American Red Cross 
The lecture will focus on the need for appropriate resolution of complex serologic cases, using all the tools in the immunohematologists toolbox, the inclusion of a personalized medicine approach to these cases. Concepts regarding RHCE allele selected products and testing with monocyte monolayer assays will be discussed. The provision of rare blood through the American Rare Donor Program and requirements for information for international requests are important to understand when rare blood is needed.  Level:  Intermediate​​
Sunday June 2

​1 contact hour
Thalassemia – Alloimmunization & Antigen Matching Practices
Clinical Care and RBC Alloimmunization for Thalassemia Patients
Presented by:  Zora Rogers, MD; Professor of Pediatrics, UT Southwestern Medical Center
This will be a brief introduction to the clinical management of persons, particularly children, with Thalassemia focusing on the use of RBC transfusion.   Level:  Intermediate​​

Matching Practices for Thalassemia - Blood Center Perspective

Presented by:  Samantha Ngamsuntikul (Gomez), MD; Associate Medical Director, South Texas Blood and Tissue Center
​Practices for Thalassemia - Blood Center Perspective  Level:  Basic
Sunday June 2

​1 contact hour
Hemoglobinopathies: The Best and the Worst
BMTs in sickle and Thalassemia patients
Presented by:  Victor Aquino, MD; Professor of Pediatrics, UT Southwestern Medical Center
The presentation will review the process and indications for bone marrow transplantation in children with sickle cell anemia and thalassemia.  Level:  Basic​

Hyperhemolysis in Sickle Cell Disease

Presented by:  Eric Gehrie, MD; Medical Director, Johns Hopkins Medical Institutions
One of the most feared complications of transfusion in the sickle cell disease population is hyperhemolysis (also known as bystander hemolysis), which is the phenomenon where a patient red blood cells are destroyed as a result of transfusion. In this case-based exercise, Dr. Gehrie will explain how to recognize this important transfusion complication, and what the laboratory should be prepared to provide to affected patients.​  Level:  Intermediate​​

Sunday June 2
1 contact hour
Nuts and Bolts: Reimbursement &  AABB IRL Standards Changes
CMS Reimbursement for Genotyping
Presented by:  Suzanne Butch, MLS(ASCP)SBB, DLM; Pathology Administration, Michigan Medicine
This session will review the billing process and codes used in billing for genotyping laboratory testing. A process for investigating denied claims will be discussed.  Level:  Intermediate​​

I Fought Law
Presented by:  Monica Kalvelage, MS, MT(ASCP)MB, SBB; Chief Operations Officer, LifeShare Blood Center 
This session is designed to review common citations issued by AABB and CAP, best behavior during an audit, and to recap changes made to the Standards, 10th edition for IRL. Level:  Intermediate​​

Sunday June 2
2 contact hours
Roundtable Discussions & Blood Bank Trivia
Roundtable Discussions

  • ABO Incompatibility in Kidney Transplants  
  • Trauma (to include helicopter transfusion, low titer O whole blood, MTP)
  • Molecular vs Serology 
  • Weak D vs Partial D
  • Hiring & Training Blood Bank Staff (including licensed programs) 
  • Out of Hospital Transfusions

Blood Bank Trivia
Presented by:  Phyllis Haines, MLS(ASCP)CM SBB; Director of Laboratory Services, The Blood Center
Blood Bank Jeopardy​.  Level:  Intermediate​​

Monday June 3


2 contact hours
Blood Group Antigens and their Expression
Modifiers of Red Cell Antigen Expression
Presented by:  Margaret Keller, PhD; Senior Director, National Molecular Laboratory, American Red Cross
There are cases where a patient or donor red cells lack an antigen or antigens, yet the gene encoding those antigens is found to be intact and without deleterious mutation. This talks aims to show how deletions or mutations elsewhere in the genome can impact antigen expression and how molecular methods can aid in determining the phenotype and blood needs.  Level:  Intermediate​​

Blood Group Review- Kidd System
Presented by:  Janis Hamilton​, MS, MT(ASCP)SBB; Manager, Immunohematology Reference Laboratory, American Red Cross-Southeastern Michigan Region
The Kidd blood group system has long been recognized as clinically important in transfusion medicine. Anti-Jka, anti-Jkb and anti-JK3 are well known for their ability to hemolyze-antigen positive red cells, even when the antibody is not detectable. DNA analysis has revealed new information about the system. Discrepancies in serological and molecular JK results, variation in JK antigen status using different reagents and apparent alloantibody in antigen-positive individuals are now often explainable. This presentation will summarize current information on Kidd system alleles, antigens and antibodies, including new findings on the molecular basis of the In(JK) null phenotype.  Level:  Intermediate​​
Monday June 3
​1 contact hour
Big C Discrepancies & Drug Interference 
C Typing Discrepancies - Genotype vs Phenotype
Presented by:  Trina Horn, MS, MLT(ASCP)SBB; Manager, National Molecular Laboratory, American Red Cross
This presentation will describe typing discrepancies involving the big C antigen in both the patient and donor populations. The molecular characteristics of the RHD and RHCE genes will be discussed and variants that may cause C typing discrepancies will be outlined. Through several case studies, the audience will experience different scenarios where the C antigen type was discordant and how molecular testing can help resolve such issues.  Level:  Intermediate​​

Attack of the Clonals: How to Deal with Anti-CD38 and Anti-CD47 Interference
Presented by:  Chris Lough, MD; Vice President of Medical Services, LifeSouth Community Blood Centers, Inc.
The rising use of monoclonal antibody therapy in patients with hematologic, and likely soon solid, malignancies has caused much consternation amongst immunohematology laboratories through interference with common testing methods. In this presentation we will review current practices available for dealing with interference secondary to anti-CD38 therapy, as well as discuss options for handling the newer monoclonal anti-CD47 agents currently in clinical trials. Case studies will be presented to illustrate approaches to workups in these patient populations. ​ Level:  Intermediate​​

Monday June 3

​1 contact hour
Case Studies
Case Study #1:  Antibody to an Antigen of High Prevalence: A Voyage into Choppy Waters
Presented by: Kristin Vail, MLS(ASCP)CM SBBCM; IRL Clinical Laboratory Supervisor, Vitalant
Presentation of case studies that involve the methods and procedures utilized in the identification of an antibody of high prevalence. Discussion of subsequent testing and the transfusion management options in such cases.  Level:  Advanced

Case Study #2
Presented by:  Phyllis Haines, MLS(ASCP)CM SBB; Director of Laboratory Services, The Blood Center
Identifying a Rh discrepancy on an donor with historical ABO/Rh on record.  Level:  Basic

Case Study #3
Presented by:  Brett Dunlap, MS, MLS(ASCP); Medical Laboratory Scientist II, Lifeshare Blood Center
A case sent for complex antibody identification, resulting in an antibody to a high incidence antigen and another underlying allo-antibody.  Level:  Advanced

Continuing Education Credits 
SCABB is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. 10 PACE Credit hours are approved for this meeting. 
SCABB is approved as a provider of Florida Continuing Education through CE Broker.